Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation

被引:9
|
作者
Akahoshi, Tomohiko [1 ,3 ]
Kaku, Noriyuki [1 ]
Shono, Yuji [1 ]
Yamamoto, Yuzo [1 ]
Takahashi, Keita [2 ]
Iyonaga, Takeshi [1 ]
Momii, Kenta [1 ]
Nishihara, Masaaki [1 ]
Maki, Jun [2 ]
Tokuda, Kentaro [2 ]
Yamaura, Ken [2 ]
机构
[1] Kyushu Univ Hosp, Emergency & Crit Care Ctr, Fukuoka, Japan
[2] Kyushu Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med Sci, Fukuoka, Japan
[3] Kyushu Univ Hosp, Emergency & Crit Care Ctr, 3 1 1 Maidashi, Higashi ku, Fukuoka 8128582, Japan
关键词
disseminated intravascular coagulation; sepsis; antithrombin activity; recombinant antithrombin gamma; CRITICALLY-ILL PATIENTS; DIAGNOSTIC-CRITERIA; EFFICACY; SAFETY; SUPPLEMENTATION; MULTICENTER; THROMBOMODULIN; HEPARIN;
D O I
10.1177/10760296221135790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant antithrombin gamma (rAT) is reported as an effective drug for patients with disseminated intravascular coagulation (DIC) in Japan. As the appropriate dose and targeted AT activity remain unknown, this study aimed to determine these aspects for sepsis-induced DIC. Thirty-one patients with septic shock and DIC with AT levels <70% were treated with rAT between May 2018 and December 2020. The recovery rates from DIC were 32.2% and 63.3% on day 3 and 5 post administration, respectively. Recovery and survival rates were significantly higher in patients who achieved AT activity >= 70% or 80% on day 3 post administration. Receiver operating characteristic curve analysis revealed that the cutoff values of post-treatment AT activity on day 3 for 28-day survival and 5-day recovery from DIC were 79.5% and 81.5%, respectively. Patients who did not achieve AT activity >= 80% on day 3 presented a lower base level of AT activity and lower dose supplementation. Our results suggest that targeted AT activity should be at least 70%, and ideally 80%, and sufficient doses to maintain this activity are required to achieve better outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Optimal Timing and Early Intervention With Anticoagulant Therapy for Sepsis-Induced Disseminated Intravascular Coagulation
    Yamakawa, Kazuma
    Umemura, Yutaka
    Murao, Shuhei
    Hayakawa, Mineji
    Fujimi, Satoshi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [32] Early Changes in the Sequential Organ Failure Assessment Score Among Patients With Sepsis-Induced Disseminated Intravascular Coagulation
    Mochizuki, Katsunori
    Mori, Kotaro
    Nakamura, Yuta
    Uchimido, Ryo
    Kamijo, Hiroshi
    Takeshige, Kanako
    Nitta, Kenichi
    Imamura, Hiroshi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 : 332S - 339S
  • [33] A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis
    Gando, Satoshi
    Saitoh, Daizoh
    Ishikura, Hiroyasu
    Ueyama, Masashi
    Otomo, Yasuhiro
    Oda, Shigeto
    Kushimoto, Shigeki
    Tanjoh, Katsuhisa
    Mayumi, Toshihiko
    Ikeda, Toshiaki
    Iba, Toshiaki
    Eguchi, Yutaka
    Okamoto, Kohji
    Ogura, Hiroshi
    Koseki, Kazuhide
    Sakamoto, Yuichiro
    Takayama, Yasuhiro
    Shirai, Kunihiro
    Takasu, Osamu
    Inoue, Yoshiaki
    Mashiko, Kunihiro
    Tsubota, Takaya
    Endo, Shigeatsu
    CRITICAL CARE, 2013, 17 (06):
  • [34] Determining prognostic indicator for anticoagulant therapy in sepsis-induced disseminated intravascular coagulation
    Iba, Toshiaki
    Yamakawa, Kazuma
    Shiko, Yuki
    Hisamune, Ryo
    Tanigawa, Tomoki
    Helms, Julie
    Levy, Jerrold H.
    JOURNAL OF INTENSIVE CARE, 2024, 12 (01):
  • [35] Sepsis-induced disseminated intravascular coagulation: an international estrangement of disease concept
    Ushio, Noritaka
    Wada, Takeshi
    Ono, Yuichiro
    Yamakawa, Kazuma
    ACUTE MEDICINE & SURGERY, 2023, 10 (01):
  • [36] Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey
    Iba, Toshiaki
    Gando, Satoshi
    Saitoh, Daizoh
    Ikeda, Toshiaki
    Anan, Hideaki
    Oda, Shigeto
    Kitamura, Nobuya
    Mori, Shigeru
    Kotani, Joji
    Kuroda, Yasuhiro
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (05) : 422 - 428
  • [37] Non-overt disseminated intravascular coagulation scoring for critically ill patients: The impact of antithrombin levels
    Egi, Moritoki
    Morimatsu, Hiroshi
    Wiedermann, Christian J.
    Tani, Makiko
    Kanazawa, Tomoyuki
    Suzuki, Satoshi
    Matsusaki, Takashi
    Shimizu, Kazuyoshi
    Toda, Yuichiro
    Iwasaki, Tatsuo
    Morita, Kiyoshi
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (04) : 696 - 705
  • [38] Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation
    Iba T.
    Saitoh D.
    Journal of Intensive Care, 2 (1)
  • [39] OPTIMAL PLASMA CONCENTRATION OF THROMBOMODULIN ALFA TO TREAT SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION
    Imaura, Masaharu
    Katagiri, Fumihiko
    Nagase, Satoshi
    Hatoyama-Tanaka, Saori
    Takahashi, Hiroyuki
    Takayanagi, Risa
    Kanno, Hiroshi
    Yamada, Yasuhiko
    SHOCK, 2023, 60 (02): : 221 - 226
  • [40] Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation
    Iba, Toshiaki
    Levy, Jerrold H.
    Raj, Aditya
    Warkentin, Theodore E.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (05)